Sign In
NewsRadar

Massive £50 million Series B round for UK-based Cell Medica

25 November 2014 13:15
By Tornado Staff

Cellular immunotherapy company Cell Medica has secured a £50 million series B funding round led by Imperial Innovations. The investor committed £15 million alongside co-investors Invesco Asset Management and Woodford Investment Management.

Cell Medica develops patient-specific products for the treatment of cancer and infectious diseases. The company’s lead oncology product, CMD-003, is under investigation in the CITADEL Phase II clinical trial for the treatment of patients with advanced lymphomas associated with the Epstein Barr virus. Comprised of the patient’s own immune cells, the product offers a targeted approach to cancer treatment with limited side effects or toxicities.

In the infectious disease field, Cell Medica is developing Cytovir CMV for the treatment of cytomegalovirus infections and Cytovir ADV for the treatment of adenovirus infections. Both applications are aimed at treating and preventing infections in patients who are immunosuppressed following a bone marrow transplant. The clinical development of Cytovir CMV has been funded in part by The Wellcome Trust.

Cell Medica received a seed funding round in 2007 from Imperial Innovations. This investor continued its support for the company, leading each of its subsequent funding rounds, including a series A investment in 2012, which brought in Invesco and CPRIT (Cancer Prevention Research Institute of Texas) as investors.



Related stories
Mucosis wins Wellcome Trust award and backing from current investors
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Big VC rounds for Ganymed and MISSION to fight cancer
Catalan medical diagnostics company STAT-Diagnostica gets €17 million


Up
Data


24,979
Tech investments
From our Online Data Service
16,165
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 9€1.5MWireless applications
Nov 9€1.6MeLearning
Nov 9€2.2MeLearning
Nov 9N/AFixed communications
Nov 9€69.0MInternet services
Nov 8€7.0MOther Biotechnology & Healthcare
Nov 8€1.0MInternet services

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom





About usContact usLegal Information
Copyright © 1999-2018
Emerging Technology Research Europe Inc. All rights reserved.